CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Greenlight Biosciences Holdings PBC is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Greenlight Biosciences Holdings PBC
29 Hartwell Avenue
Phone: (617) 616-8188p:617 616-8188 LEXINGTON, MA  02421  United States Fax: (302) 636-5454f:302 636-5454
This company ceased filing statements with the SEC on 8/11/2023.
On 7/24/2023, the Company completed its Go-Private transaction with a consortium led by Fall Line Endurance Fund
This company is no longer actively traded on any major stock exchange.
Business Summary
GreenLight Biosciences Holdings, PBC is a pre-commercial stage biotechnology company. The Company has a cell-free ribonucleic acid (RNA) production platform for the discovery, development, and commercialization of products to promote healthier plants, foods, and people. The Company's cell-free biomanufacturing platform enables the making of complex biological molecules-nucleic acids, peptides, carbohydrates, and many others using fermentation. Its technology platform provides integrated discovery, design, and development of RNA-based products used in advanced pharma discovery to agriculture and human health. It has developed two manufacturing processes, one for plant health (dsRNA) and one for human health (mRNA) that both rely on synthesis of RNA from RNA building blocks, enzymes, and deoxyribonucleic acid (DNA) templates. The Company's plant program includes the Colorado Potato Beetle Program-Calantha; Varroa Mite Program, and Powdery Mildew Complex.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-YesYesYes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202312/31/2022YesYes---

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Charles L.Cooney 77 2/1/2022 2/1/2022
President, Chief Executive Officer, Co-Founder, Director Andrey J.Zarur 52 2/1/2022 2/1/2022
Chief Financial Officer SusanKeefe 50 5/1/2019 5/1/2019
8 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
GreenLight Biosciences, LLC 200 Boston Ave. Medford MA United States

Business Names
Business Name
GreenLight Biosciences Espana, S.L.
GreenLight Biosciences Inc.
GreenLight Biosciences, Inc.
GreenLight Pandemic Response, Inc.
GreenLight Security Corporation
GRNA

General Information
Number of Employees: 262 (As of 3/15/2023)
Outstanding Shares: 151,681,314 (As of 5/8/2023)
Shareholders: 131
Stock Exchange: NASD
Federal Tax Id: 851914700
Fax Number: (302) 636-5454
Email Address: contact@greenlightbiosciences.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, April 28, 2024